Claims
- 1. A method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor in a mammal, said method comprising administering to said mammal an effective amount of a selective alpha-2B-adrenoceptor antagonist, wherein said antagonist is a compound selected from the group consisting of compounds A, B, C and E, or a pharmaceutically acceptable salt of said compound, wherein said compounds A, B, C and E have the following structures:
- 2. The method according to claim 1, wherein the disease is a coronary heart disease (CHD).
- 3. The method according to claim 2, wherein the disease isacute myocardial infarction (AMI), unstable angina pectoris, Prinzmetal's variant form of angina pectouis, other forms of chronic angina pectotis and CHD, or restenosis after coroniary angioplasty.
- 4. The method according to claim 1, wherein the disease is essential hypertension.
- 5. The method according to claim 1, wherein the disease is a vascular disesase, which isvasoconstriction or hypoxic brain damage subsequent to subarachloid haemorrhage, migraine, Raynaud's disease or cold intolerance, pre-eclampsia, male erectile dysfunction, or obesity.
- 6. The method according to claim 1, wherein said alpha-2B-adrenoceptor antagonist is administered to a mammal to potentiate the clinical efficacy of an anesthetic and/or analgetic alpha-2-adrenoceptor agonist, said agonist not being selective for the alpha-2B-adrenoceptor subtype.
- 7. The method according to claim 1, wherein said alpha-2B-adrenoceptor antagonist is administered to an individual having a deletion of 3 glutamates from the glutanic acid repeat element of 12 glutamates (amino acids 297-309), in an acid strech of 17 amino acids, located in the third intracellular loop of the receptor polypeptide.
- 8. The method according to claim 7 wherein said individual is a deletion/deletion genotype.
Parent Case Info
This application claims priority of U.S. provisional application Ser. No. 60/182,021, filed Feb. 11, 2000.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4604398 |
Ward |
Aug 1986 |
A |
5292740 |
Burri et al. |
Mar 1994 |
A |
5530118 |
Oinuma et al. |
Jun 1996 |
A |
Non-Patent Literature Citations (4)
Entry |
*Fujikura et al., “Studies on Benzenesulfonamide Derivatives With .alpha.-and .beta.-adrenergic Antagonistic and Antihypertensive Activities.” 98 STN Int'l 178855 (1982). |
Michel et al., “Assessment of Imiloxan as a Selective α2B-adrenoceptor Antagonist,” 99 Br. J. Pharmacol. 560 (1990). |
Link et al., “Cardiovascular Regulation in Mice Lacking α2-adrenergic Receptor Subtypes b and c,” 273 Science 803 (1996). |
MacDonald et al., “Gene Targeting—Homing in on α2-Adrenoceptor-subtype Function,” 18 Trends Pharmacol Sci 211 (1997). |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/182021 |
Feb 2000 |
US |